Compare SRPT & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | INSP |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2000 | 2018 |
| Metric | SRPT | INSP |
|---|---|---|
| Price | $22.03 | $60.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 16 |
| Target Price | $25.85 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 2.9M | 605.3K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | ★ 2.99 | N/A |
| Revenue | ★ $2,198,237,000.00 | $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | N/A | $8.11 |
| P/E Ratio | $7.22 | ★ N/A |
| Revenue Growth | 15.58 | ★ 62.18 |
| 52 Week Low | $14.68 | $38.91 |
| 52 Week High | $25.32 | $147.03 |
| Indicator | SRPT | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 72.39 | 60.68 |
| Support Level | $20.12 | $56.50 |
| Resistance Level | $23.71 | $61.32 |
| Average True Range (ATR) | 1.08 | 2.21 |
| MACD | 0.33 | -0.10 |
| Stochastic Oscillator | 90.82 | 71.01 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.